This grant, offered by the National Institutes of Health, is for supporting preclinical activities focused on developing innovative long-acting/sustained release (LA/SR) technologies. The primary purpose is to create safe and effective LA/SR products for preventing and treating HIV, along with associated co-infections such as tuberculosis (TB), hepatitis B (HBV), and hepatitis C (HCV). A key objective is to advance these promising therapies towards an Investigational New Drug (IND) application submission to the U.S. Food and Drug Administration (FDA). Eligible LA/SR products must demonstrate strong scientific rationale, competitive advantages, and proven effectiveness in relevant non-clinical or animal models, exhibiting efficacy with intermittent single-dose or continuous-dosing regimens like injections, implants, or patches.
Opportunity ID: 357333
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-AI-24-076 |
| Funding Opportunity Title: | Advancing Translation of Long-Acting Strategies for HIV and HIV-Associated Co-infections (AT LASt) (R61/R33 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.855 — Allergy and Infectious Diseases Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Nov 22, 2024 |
| Last Updated Date: | Nov 22, 2024 |
| Original Closing Date for Applications: | Mar 13, 2025 |
| Current Closing Date for Applications: | Mar 13, 2025 |
| Archive Date: | Apr 18, 2025 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | County governments For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments Public and State controlled institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Native American tribal governments (Federally recognized) Private institutions of higher education Small businesses Special district governments Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this notice of funding opportunity (NOFO) is to support preclinical activities for the development of safe and effective long-acting/sustained release (LA/SR) technologies for prevention and treatment of HIV and HIV-associated tuberculosis (TB), hepatitis B (HBV) and hepatitis C (HCV), and to ultimately advance these products toward submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). Solicited LA/SR products will have demonstrated strong rationale, competitive advantage, and effectiveness in appropriate non-clinical or animal models at intermittent dosing from either a single administration (injection, topical, oral administration) or continuous dosing regimen (implant, transdermal patch, etc.). |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-076.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 357333 Full Announcement-RFA-AI-24-076 -> RFA-AI-24-076-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-I | Use for due dates on or after January 25, 2025 | PKG00288949 | Feb 13, 2025 | Mar 13, 2025 | View |
Package 1
Mandatory forms
357333 RR_SF424_5_0-5.0.pdf
357333 PHS398_CoverPageSupplement_5_0-5.0.pdf
357333 RR_OtherProjectInfo_1_4-1.4.pdf
357333 PerformanceSite_4_0-4.0.pdf
357333 RR_KeyPersonExpanded_4_0-4.0.pdf
357333 RR_Budget10_3_0-3.0.pdf
357333 PHS398_ResearchPlan_5_0-5.0.pdf
357333 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
357333 RR_SubawardBudget10_30_3_0-3.0.pdf
357333 PHS_AssignmentRequestForm_4_0-4.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
